We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+39.82%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$11.4B
AUM Growth
+$3.47B
Cap. Flow
+$1.27B
Cap. Flow %
11.12%
Top 10 Hldgs %
37.58%
Holding
169
New
25
Increased
27
Reduced
20
Closed
20

Top Buys

Rank Stock Value
1
ABCL icon
AbCellera Biologics
ABCL
+$384M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$292M
3
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$154M
4
PFE icon
Pfizer
PFE
+$133M
5
UNH icon
UnitedHealth
UNH
+$131M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$259M
2
XLRN
Acceleron Pharma
XLRN
+$67.6M
3
ASND icon
Ascendis Pharma A/S
ASND
+$65.8M
4
EXEL icon
Exelixis
EXEL
+$58.8M
5
BIIB icon
Biogen
BIIB
+$48.1M

Sector Composition

Rank Sector Weight
1 Healthcare 98.2%
2 Financials 0.52%
3 Technology 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KROS icon
26
Keros Therapeutics
KROS
$199M
$118M 1.04%
1,679,417
– –
RPTX
27
DELISTED
Repare Therapeutics
RPTX
$118M 1.03%
3,426,325
– –
HUM icon
28
Humana
HUM
$46.7B
$117M 1.03%
286,100
+5,800
+2% +$2.41M
TBPH icon
29
Theravance Biopharma
TBPH
$875M
$111M 0.97%
6,219,110
– –
NSTG
30
DELISTED
NanoString Technologies, Inc.
NSTG
$109M 0.95%
1,626,900
+443,800
+38% +$22.3M
DXCM icon
31
DexCom
DXCM
$28.9B
$103M 0.9%
1,116,400
+210,800
+23% +$18.8M
ELV icon
32
Elevance Health
ELV
$83.7B
$99.7M 0.87%
+310,500
New +$95.3M
ORIC icon
33
Oric Pharmaceuticals
ORIC
$1.23B
$98.9M 0.87%
2,921,967
– –
BNR
34
Burning Rock Biotech
BNR
$96.9M
$96.1M 0.84%
416,168
-58,440
-12% -$15.7M
AGIO icon
35
Agios Pharmaceuticals
AGIO
$2.14B
$95.6M 0.84%
2,207,321
– –
ACET icon
36
Adicet Bio
ACET
$76.7M
$94.3M 0.82%
419,282
– –
EW icon
37
Edwards Lifesciences
EW
$48.2B
$93.6M 0.82%
1,025,800
+319,300
+45% +$26.5M
ABBV icon
38
AbbVie
ABBV
$465B
$92.4M 0.81%
862,300
+398,300
+86% +$38.3M
ISRG icon
39
Intuitive Surgical
ISRG
$130B
$92.3M 0.81%
338,400
– –
SRPT icon
40
Sarepta Therapeutics
SRPT
$1.63B
$91.9M 0.8%
539,049
– –
ETNB
41
DELISTED
89bio
ETNB
$90.9M 0.8%
3,729,442
– –
XTNT icon
42
Xtant Medical Holdings
XTNT
$59.7M
$87.1M 0.76%
72,803,072
+63,554,394
+687% +$81.8M
SVA
43
DELISTED
Sinovac Biotech, Ltd
SVA
$72M 0.63%
2,839,500
– –
PGNY icon
44
Progyny
PGNY
$2.41B
$71M 0.62%
1,675,500
– –
GH icon
45
Guardant Health
GH
$19B
$69.4M 0.61%
538,200
+383,900
+249% +$44.2M
CRSP icon
46
CRISPR Therapeutics
CRSP
$4.68B
$69.2M 0.61%
451,800
-178,204
-28% -$21.1M
ATRC icon
47
AtriCure
ATRC
$2.02B
$68.4M 0.6%
1,228,189
– –
TCDA
48
DELISTED
Tricida, Inc. Common Stock
TCDA
$67.8M 0.59%
9,614,280
– –
AUPH icon
49
Aurinia Pharmaceuticals
AUPH
$1.92B
$65.7M 0.58%
4,754,000
– –
LOGC
50
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$64.6M 0.57%
8,466,783
+2,000,000
+31% +$13.4M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2020 Portfolio in Review

As of Q4 2020, OrbiMed held 169 positions worth $11.4B, up 44% from $7.96B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed deployed $1.27B of net new capital in Q4 2020, opening 25 new positions and adding to 27 existing holdings. Its largest new stake was AbCellera Biologics: 8,400,768 shares worth $338M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $259M trimmed.

  • OrbiMed's largest Q4 2020 buy was AbCellera Biologics: 8,400,768 shares worth $338M.
  • OrbiMed added most to Xtant Medical Holdings in Q4 2020, an estimated $81.8M increase.
  • OrbiMed's biggest Q4 2020 reduction was Alexion Pharmaceuticals, cutting an estimated $259M.
  • OrbiMed fully exited Acceleron Pharma in Q4 2020, selling an estimated $67.6M.
  • OrbiMed's ten largest holdings make up 38% of its $11.4B portfolio in Q4 2020.
  • OrbiMed opened 25 new positions and closed 20 in Q4 2020.
  • OrbiMed's portfolio value rose 44% quarter-over-quarter to $11.4B.

Based on OrbiMed's 13F filing for Q4 2020, filed 16 Feb 2021.